Intuitive Surgical beat Q1 expectations and raised its full-year 2026 guidance, now projecting da Vinci procedure growth of 13.5% to 15.5%. The upside was driven by stronger robotic surgery adoption in both the United States and Europe. The company is also expanding its Force Feedback technology across the da Vinci platform, adding a new capability edge to its already dominant market position.
Intuitive Surgical is the clear market leader in surgical robotics, so a raised outlook signals genuine demand acceleration — not just a one-quarter beat. Investors in ISRG directly benefit, but the guidance upgrade also lifts sentiment across the broader medical device and surgical robotics space. Rising procedure volumes are a high-quality revenue signal because they reflect recurring usage, not one-time hardware sales.
July 2025: Intuitive Surgical Q2 earnings report (exact date TBD). Watch for any FDA updates on Force Feedback technology clearance or expanded indications for da Vinci systems.
Full analysis · Subscribers
The deep dive (bull case, bear case, and the data point that decides which side wins), the cause-and-effect chain behind the move, plain-English explainers for every block.
Aggregated reads dozens of sources in five languages and turns the day into plain-English cards like this one.
Educational analysis of public information, not investment advice. Report an error · Corrections policy
← Today's brief